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Abstract
Background: Pancreatic cancer is one of the most aggressive cancers, with tumor-induced myeloid-derived suppressor cells
(MDSC) contributing to its pathogenesis and ineffective therapies. In response to cytokine/chemokine receptor activation,
src homology 2 domain-containing inositol 59-phosphatase-1 (SHIP-1) influences phosphatidylinositol-3-kinase (PI3K)
signaling events, which regulate immunohomeostasis. We hypothesize that factors from murine pancreatic cancer cells
cause the down-regulation of SHIP-1 expression, which may potentially contribute to MDSC expansion, and the suppression
of CD8
+ T cell immune responses. Therefore, we sought to determine the role of SHIP-1 in solid tumor progression, such as
murine pancreatic cancer.
Methodology and Principal Findings: Immunocompetent C57BL/6 mice were inoculated with either murine Panc02 cells
(tumor-bearing [TB] mice) or Phosphate Buffer Saline (PBS) (control mice). Cytometric Bead Array (CBA) analysis of
supernatants of cultured Panc02 detected pro-inflammatory cytokines such as IL-6, IL-10 and MCP-1. TB mice showed a
significant increase in serum levels of pro-inflammatory factors IL-6 and MCP-1 measured by CBA. qRT-PCR and Western blot
analyses revealed the in vivo down-regulation of SHIP-1 expression in splenocytes from TB mice. Western blot analyses also
detected reduced SHIP-1 activity, increased AKT-1 and BAD hyper-phosphorylation and up-regulation of BCL-2 expression in
splenocytes from TB mice. In vitro, qRT-PCR and Western blot analyses detected reduced SHIP-1 mRNA and protein
expression in control splenocytes co-cultured with Panc02 cells. Flow cytometry results showed significant expansion of
MDSC in peripheral blood and splenocytes from TB mice. AutoMACS sorted TB MDSC exhibited hyper-phosphorylation of
AKT-1 and over-expression of BCL-2 detected by western blot analysis. TB MDSC significantly suppressed antigen-specific
CD8
+ T cell immune responses in vitro.
Conclusion/Significance: SHIP-1 may regulate immune development that impacts MDSC expansion and function,
contributing to pancreatic tumor progression. Thus, SHIP-1 can be a potential therapeutic target to help restore
immunohomeostasis and improve therapeutic responses in patients with pancreatic cancer.
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Introduction
Pancreatic cancer is a fatal malignancy, ranking as the fourth
most common cause of cancer-related mortalities in the United
States [1]. Pancreatic cancer prognoses are poor due to its late
detection, leading to advanced stages and inoperability at
presentation, in most patients [1]. In addition, pancreatic cancer
is resistant to a majority of chemotherapies, radiation and
immunotherapies [2]. The standard chemotherapeutic drug for
pancreatic cancer treatment is Gemcitabine [2]. Gemcitabine
prolongs survival, provides short-term symptomatic improvement
in only a few patients and rarely leads to cures [2]. Pancreatic
tumor-bearing hosts release soluble inflammatory factors that lead
to the expansion of immunosuppressive myeloid-derived suppres-
sor cells (MDSC) [3]. MDSC suppress CD8
+ T cell responses thus
curtailing the efficacy of a plethora of cancer therapies [4].
Therefore, it is imperative to understand the molecular signaling
events that regulate MDSC homeostasis and function in a
pancreatic tumor microenvironment. The identification of new
molecular targets is critical to improve anti-tumor immune
responses against pancreatic cancer.
Src homology 2 domain-containing inositol 59 -phosphatase
(SHIP-1), a 145-kDa protein, is a critical regulator of numerous
biological processes in hematopoietic cells such as proliferation,
differentiation, activation, migration, and survival/apoptosis, via
its ability to regulate the phosphatidylinositol-3-kinase (PI3K)
pathway [5]. In response to cytokine or growth factor signaling,
the PI3K phospholipid product PIP3 recruits pleckstrin homology
(PH) domain containing kinases such as protein kinase B (PKB also
known as AKT) [6]. AKT regulates apoptosis/survival signaling
events that influence the outcome of immune responses [6]. SHIP-
1, or SHIP-2 (an isoform expressed in non-hematopoietic and
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signaling pathways by hydrolyzing PI-3,4,5-P3 phospholipid
product to yield PI-3,4-P2, thus maintaining immune cell
homeostasis [5]. SHIP-1 has recently been implicated as a possible
tumor suppressor in hematopoietic cancers [5] as its protein
expression is notably reduced or mutated in many leukemias and
lymphomas [8,9,10,11]. However, SHIP-1’s role in solid tumor
progression has not been fully investigated. SHIP-2 has not been
identified as a tumor suppressor but there is preliminary evidence
that suggests it may promote tumor progression [12,13]. Thus, the
regulation of PI3K pathways is important to maintain immune
homeostasis and prevent tumorigenesis [5].
SHIP deficient mice have perturbed cytokine and chemokine
production resulting in a pro-inflammatory phenotype [14].
Myeloid progenitors of SHIP deficient mice are highly responsive
to modulation with cytokine, growth factors or chemokines in
comparison to their wild-type counterparts [14,15]. As a result,
SHIP deficient mice develop splenomegaly, due to increased
myelopoiesis [14]. They also develop a myeloproliferative disease
(MPD) with some resemblance to chronic myeloid leukemia
(CML) in humans [14]. Ghansah et al reported that SHIP
deficient mice have a significant expansion of immunosuppressive
Gr1
+CD11b
+ MDSC, which prevented allograft rejection by
suppressing allogeneic T cell responses in vivo and in vitro [16,17].
MDSC are a heterogeneous population of immature myeloid cells
that expand due to changes in the microenvironment in response
to inflammation/cancer, ultimately suppressing T cell responses
by a variety of mechanisms [18]. A significant expansion of
immunosuppressive regulatory T cells (Treg), which can also lead
to suppression of T cell immune responses, is observed in SHIP
deficient mice [19]. SHIP deficient mice are also noted to have an
expansion of macrophages that secrete high levels of IL-6 in
response to increasing IgG production [20]. This in turn leads to
reduced B cell percentages and enhanced myeloid-cell develop-
ment in these mice [21]. SHIP deficient mice are potentially more
susceptible to the facilitation of solid tumor growth [5] which is
likely due to the loss of immune cell homeostasis.
In this study, we evaluated the role of SHIP-1 in the
development of non-hematopoietic cancer (solid pancreatic tumor)
and its effects on immunosuppressive leukocytes. We hypothesized
that murine pancreatic cancer creates an inflammatory environ-
ment, which alters the expression of SHIP-1 in leukocytes.
Furthermore, this altered SHIP-1 expression negatively affects
MDSC homeostasis and function, thus suppressing anti-tumor
immune responses. Therefore, we propose that SHIP-1 may act as
a tumor suppressor and a therapeutic target for the treatment of
non-hematopoietic solid tumors such as pancreatic cancer.
Results
Murine Panc02 cells modulate pro-inflammatory factors
in vivo
Tumor-derived soluble factors, such as cytokines and chemo-
kines, in the tumor microenvironment can modulate leukocyte
development and influence immune responses [22]. Therefore, we
wanted to evaluate the pro-inflammatory factors produced by
murine Panc02 cells in vitro. Results from the Inflammatory
Cytometric Bead Analysis (CBA) Kit detected pro-inflammatory
factors Interleukin-6 (IL-6), Interleukin-10 (IL-10) and Monocyte
Chemoattractant Protein-1 (MCP-1) to a greater extent than
Tumor Necrosis Factor (TNF), Interferon gamma (IFN-c and
Interleukin-12p 70 (IL-12p70) in the supernatants of cultured
murine Panc02 cells (Figure 1a). Next, 1.5610
5 murine Panc02
cells were subcutaneously inoculated into C57BL/6 mice
(tumor-bearing mice (TB)). Control mice received Phosphate
Buffer Saline (PBS). Post tumor inoculation, we evaluated tumor
progression and weight of TB mice for approximately 30 days. An
exponential increase in tumor growth was observed in TB mice
(Figure 1b) but no significant difference was seen in weight of TB
compared to control mice (data not shown). We observed that TB
mice usually succumbed to death within 25–30 days post Panc02
inoculation, depending on tumor load. Serum was evaluated to
determine whether there were changes in the production of pro-
inflammatory factors in TB mice. CBA analysis revealed a
significant increase in the production of pro-inflammatory factors
IL-6 and MCP-1 but no significant change in the production of
IL-10, TNF, IFN-c or IL-12p70 in serum collected from TB
compared to control mice (Figure 1c). Spleens from TB mice
exhibited splenomegaly and weighed significantly more compared
to those from control mice (Figure 2a and 2b). It is important to
note that spleens from TB mice have a similar phenotype to
spleens from SHIP deficient mice with significant splenomegaly
observed in both [14].
TB splenocytes have a reduction in SHIP-1 expression
SHIP expression is sensitive to cytokine/chemokine responses
and immune stress [23]. Therefore, we hypothesized that SHIP-1
expression would be altered in our pancreatic TB mice due to an
increase in the pro-inflammatory factors we observed in these
mice. Western blot analyses revealed reduced SHIP-1 protein
expression in the splenocytes from TB compared to control mice
(Figure 3a). This SHIP-1 antibody recognizes the carboxy
terminus of mouse origin. Next, we wanted to investigate whether
the reduction in SHIP-1 protein expression in TB splenocytes was
due to a transcriptional or post-translational event. Quantitative
Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
results detected a decrease in SHIP-1 mRNA expression in TB
compared to control splenocytes (Figure 3b). We then evaluated
SHIP-2 and PTEN protein expression, which are both critical
inositol phosphatases that hydrolyze the PI3K phospholipid
product PI-3,4,5-P3 [5]. Western blot results revealed no
significant difference in the protein expression of SHIP-2 or
PTEN in splenocytes from TB compared to control mice
(Figure 3c and 3d). Thus far, our data suggests that a pancreatic
tumor-induced inflammatory microenvironment alters SHIP-1
protein expression and may potentially affect downstream
survival/apoptotic-signaling pathways in immune cells.
TB splenocytes have reduced SHIP-1 activity
Phosphorylation of SHIP-1 on tyrosine residues (917 and 1020)
causes it to associate with the adapter protein Shc and translocate
to the plasma membrane, which is crucial for its enzymatic activity
[24,25,26]. We therefore evaluated the phosphorylation status of
SHIP-1 in our TB mice. Western blot analyses did not detect
phosphorylation of tyrosine 1020 on SHIP-1, in splenocytes from
TB compared to control mice (Figure 4a). This particular
phospho-SHIP 1020 antibody recognizes endogenous level of
SHIP-1 in human, mouse and rat. We were unable to evaluate
tyrosine phosphorylation of residue 917 on SHIP-1 proteins
expressed in lysates from TB and control mice, as there are no
commercially available antibodies.
TB splenocytes have increased AKT activity
SHIP ablation, reduction in its expression or loss of its function
due to mutations, leads to constitutively activated AKT/PKB and
its downstream signaling events that regulate cell survival [5].
Therefore, we examined whether AKT/PKB, a downstream
target of SHIP-1, was hyper-phosphorylated in splenocytes
SHIP-1 in Murine Pancreatic Cancer
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revealed hyper-phosphorylation of AKT-1 at Ser473 in whole
splenocytes from TB compared to control mice (Figure 4b). Total
AKT levels were detected by using an AKT1/2/3 specific
antibody, which showed no difference in AKT protein expression
between TB and control splenocytes. It is important to note that
phosphorylation at Thr308 and Ser473 are both required for full
activation of AKT/PKB [27]. However, western blot analyses did
not detect phosphorylation of AKT-1 at Thr308 in TB compared
to control mice (data not shown). Therefore, phosphorylation of
AKT-1 at Ser473 alone may alter homeostasis and function of
immune cells in this murine pancreatic tumor model.
Figure 1. Increase in Pro-inflammatory factors in murine Panc02 cells and TB mice. (A) Pro-inflammatory cytokine production by Panc02
cells as determined by CBA and flow cytometry analysis of culture supernatant. (B) Growth curve of TB mice inoculated with murine Panc02 cells. (C)
Cytokine profiles of TB and control mice as measured by CBA assay. Represented is the mean 6 S.E.M. of control (n=4) compared to TB (n=4) mice.
***p,0.001 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g001
Figure 2. Splenomegaly in TB mice. (A) Spleens from TB and control. mice. (B) Weights of spleens from TB and control mice. Represented is the
mean 6 S.E.M. of control (n=4) compared to TB (n=4) mice. ***p,0.001; *p,0.05 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g002
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Next, we wanted to examine the phosphorylation and expression
of B-cell lymphoma 2 Associated Death promoter (BAD), a key pro-
apoptotic protein upstream of B-cell lymphoma 2 (BCL-2) and
regulated by AKT activity [28]. Western Blot results showed hyper-
phosphorylation of BAD at Ser112 in splenocytes from TB mice
compared to control mice (Figure 4c). However, total protein
expression of BAD did not change (Figure 4c). Phosphorylated
BAD is sequestered in the cytosol, which causes the release of anti-
apoptotic protein, BCL-2 [28]. It has been reported that the over-
expression of BCL-2 in many cancers leads to the loss of leukocyte
homeostasis and their resistance to normal apoptotic processes
[29,30]. Therefore, we examined whether there was a difference in
the expression of BCL-2 in splenocytes from TB and control mice.
Western blot results revealed an up-regulation in BCL-2 expression
in splenocytes from TB mice (Figure 4d) compared to control.
Thus far, our western blot data suggests that survival pathways may
be activated in leukocytes from TB compared to control mice likely
as a result of suppression of SHIP-1 expression by the pancreatic
tumor microenvironment.
Murine Panc02 cells down-regulate SHIP-1 expression in
vitro
Hematopoietic cell proliferation and survival is regulated by
SHIP-1 mRNA and protein expression which is cytokine-
dependent [31,32,33,34]. Thus far, our in vivo data shows that
murine Panc02 inoculation into immunocompetent mice sup-
presses SHIP-1 expression, thereby potentially negatively affecting
leukocyte homeostasis. However, to determine whether Panc02
tumor cells down-regulate SHIP-1 expression, outside of the
context of in vivo cellular interactions, we performed an in vitro
assay with murine Panc02 cells and control splenocytes. qRT-PCR
analysis revealed a significant decrease in SHIP-1 mRNA
expression in control splenocytes co-cultured with Panc02 cells
compared to control splenocytes cultured alone (Figure 5a). In
addition, western blot results revealed greater than a a 2-fold
reduction in SHIP-1 protein expression in control splenocytes co-
cultured with Panc02 cells compared to control splenocytes
cultured alone (Figure 5b). Western blot results also showed that
Panc02 cells do not express SHIP-1 (Figure 5b). Representative
western blot data of SHIP-1 expression in Figure 5b was
quantified using densitometry analysis (Figure 5c). These results
correlate with our in vivo data and show that Panc02 cells are able
to suppress SHIP-1 mRNA and protein expression in vitro.
TB splenocytes have loss of homeostasis of MDSC
MDSC activation and accumulation are driven by multiple
factors associated with pro-inflammatory cytokines produced
mainly by tumor cells [35]. In addition, MDSC and myeloid cells
are expanded in SHIP deficient mice and are resistant to apoptosis
possibly due to the constitutive activation of AKT/PKB [15].
Since our western blot data showed down-regulation of SHIP-1
protein expression and activation of several pro-survival proteins
in splenocytes from TB mice, we wanted to determine if there was
an expansion of MDSC in these mice. Flow cytometry results
revealed a significant expansion of Gr-1
+CD11b
+ MDSC in
Figure 3. Down-regulation of SHIP-1 in splenocytes from TB mice. (A) Western blot analysis of SHIP-1 protein expression in whole
splenocytes from control and TB mice. *(B) qRT-PCR analysis of SHIP-1 mRNA expression in whole splenocytes from control and TB mice. (C) Western
blot analysis of SHIP-2 protein expression in whole splenocytes from control and TB mice. (D) PTEN protein expression in whole splenocytes from
control and TB mice. To control for equal protein loading the blot was re-probed with an antibody specific for b-actin. *Represented is the mean 6
S.E.M. of control (n=3) compared to TB (n=3) mice. p,0.05 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g003
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(Figure 6c and 6d) of TB compared to control mice. These results
suggestthatmurinepancreaticcancercausesthedown-regulationof
SHIP-1 expression which, directly or indirectly, negatively affects
immune cell development and may lead to exacerbated suppression
of anti-tumor immunity in pancreatic TB mice.
TB MDSC suppress Ag-specific T cell responses in vitro
SHIP deficiency leads to an expansion of MDSC and a
suppression of T cell immune responses in mice [16,17]. As
previously shown, flow cytometry results revealed a significant
expansion of MDSC in TB splenocytes (Figure 6c and 6d). Next
we purified Gr-1
+ cells (MDSC) from TB and control splenocytes
using autoMACS enrichment and made protein lysates of these
Gr-1
+ cells. Western blot data showed that Gr1
+ cells (MDSC)
from splenocytes from TB mice had hyper-phosphorylated AKT-1
and over expressed BCL-2 compared to Gr1
+ cells from control
mice (Figure 7a). Since our western blot data firmly suggests a
loss of homeostasis due to an increase in AKT-1 activity and up-
regulation of BCL-2 expression, we then wanted to examine if
there are any functional differences in TB MDSC (Gr1
+ cells)
compared to control. To examine suppressor activity, Gr1
+ cells
were purified from splenocytes of control and TB mice as
previously described and added to a culture of OT-I cells
(OVASIINFEKL-specific CD8
+ T cells) stimulated with dendritic
cells (DC) pulsed with OVASIINFEKL peptide. Proliferation was
measured by
3H-thymidine uptake. As shown in Figure 7b, both
control and TB MDSC (Gr1
+ cells) were capable of suppressing T
cell proliferation. However, a significant increase in suppressor
function was measured in TB MDSC compared to control
MDSC. These results strongly illustrate that TB MDSC (Gr1
+
cells) exhibit increased suppression of antigen-specific CD8
+ T cell
immune responses on a cell-to-cell basis in comparison to control
MDSC. This implies that MDSC from pancreatic tumor
microenvironment may be functionally suppressive and may
contribute to the aggressive nature of pancreatic cancer.
Discussion
SHIP-1, as a negative regulator of PI3K signaling in
hematopoietic cells, plays a critical role in hematological
malignancies [5]. SHIP-1 has recently been proposed to function
as a tumor suppressor in leukemias and lymphomas [8,9,10,11].
However, the role of SHIP-1 in solid malignancies has not been
fully investigated. In this study, we demonstrated that SHIP-1 may
play a role in the progression of pancreatic tumors by altering the
homeostasis and function of immunosuppressive MDSC and
potentially other immune cells. Our studies suggest that SHIP-1
may act as a tumor suppressor and may be a novel therapeutic
target for the reduction of tumor-induced immune suppression.
Panc02 cells secrete a number of inflammatory factors in vitro.
Inoculation of mice with Panc02 cells led to an inflammatory
phenotype in vivo and significant splenomegaly in Panc02 TB mice.
Differences in cytokine production of in vitro cultured Panc02 cells
compared to in vivo TB serum can be attributed to the vast array of
tumor-cell interactions that occur in vivo. Reduced expression of
SHIP-1 in TB splenocytes may be the result of the increased
Figure 4. Activation of pro-survival pathways in splenocytes TB mice. (A) Western blot analysis of phospho-SHIP-1 (Tyr1020) expression in
whole splenocytes from control and TB mice. (B) Western blot analysis of phospho-AKT-1 (Ser473) and AKT 1/2/3 protein expression in whole
splenocytes from control and TB mice. (C) Western blot analysis of phospho-BAD (Ser112) and BAD protein expression in whole splenocytes from
control and TB mice, (D) Western blot analysis of BCL-2 protein expression in whole splenocytes from control and TB mice. To control for equal
protein loading the blot was re-probed with an antibody specific for b-actin. Control (n=3) compared to TB (n=3) mice.
doi:10.1371/journal.pone.0027729.g004
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culture of control splenocytes with Panc02 cells show that Panc02
factors (soluble and non-soluble) down-regulate SHIP-1 mRNA
and protein expression in vitro. Recently, research findings have
identified a number of transcription factors and particular
microRNAs as regulators of SHIP-1 gene expression [10,36,
37,38]. These and other potential cytokine-dependent transcrip-
tional regulators of SHIP-1 expression and lymphocyte develop-
ment are currently being investigated.
The PI3K/AKT pathway is constitutively activated in some
pancreatic cancers [39]. SHIP-1 negatively regulates PI3K/AKT
pathways, which control apoptosis/survival in hematopoietic cells
[40]. In this study, not only did we observe suppressed SHIP-1
expression in this pancreatic tumor microenvironment but also
reduced SHIP-1 activity. This is indicated by the absence of SHIP-
1 phosphorylation at tyrosine residue 1020 as well as by the
activation of PI3K pro-survival pathways in TB compared to
control splenocytes. Results in our model are consistent with
findings that suggest that the absence of SHIP-1 expression results
in perturbed cytokine levels that influence and regulate the
outcome of immune responses [41].
IL-6 and MCP-1 have been characterized as key soluble factors
in MDSC induction and migration, respectively [42,43]. SHIP
deficient mice have an increase in IL-6 production in their serum,
which skews hematopoiesis, causes a suppression of B lymphopoi-
esis and increases cytokine-induced myeloid proliferation
[7,21,44]. SHIP-1 has also been found to negatively regulate
MCP-1 production in vitro [45]. In our TB mice, we report a
significant increase in both IL-6 and MCP-1 in their serum. We
also report an expansion of MDSC in the peripheral blood and
splenocytes of TB mice, but a reduction in their B cell percentages
(data not shown). It therefore appears that our TB mice show
multiple defects in myelopoiesis and lymphopoiesis that may be
due to a reduction in SHIP-1 expression similar to that observed in
SHIP deficient mice [20].
Expanded myeloid cells are more resistant to apoptosis in SHIP
deficient mice [15]. In our study, the hyper-phosphorylation of
AKT-1 and over expression of BCL-2 in sorted TB MDSC (Gr-1
+
cells) suggests that these cells may be resistant to programmed cell
death causing them to accumulate in the spleen. It also appears
that these TB MDSC are functionally more suppressive compared
to control, on a cell-to-cell basis. This indicates a possible
Figure 5. Down-regulation of SHIP-1 in control splenocytes co-cultured with Panc02 cells. *(A) qRT-PCR analysis of SHIP-1 mRNA
expression in control splenocytes alone and control splenocytes co-cultured with Panc02 cells in vitro.( B) Western blot analysis of SHIP-1 protein
expression in Panc02 cells, control splenocytes and control splenocytes co-cultured with Panc02 cells in vitro. To control for equal protein loading the
blot was re-probed with an antibody specific for b-actin. (C) Representative densitometric quantification of western blot data in panel B.
*Represented is the mean 6 S.E.M. of three independent experiments. p,0.05 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g005
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and control mice. Shown are representative flow cytometry results of Mac-1
+Gr-1
+ MDSC. (B) Represented is the Mean 6 S.E.M of the relative
percentages of MDSC in TB and control mice. (C) MDSC percentages in splenocytes (SP) from TB and control mice. Shown are representative flow
cytometry results of Mac-1
+Gr-1
+ MDSC. (D) Represented is the Mean 6 S.E.M of the relative percentages of MDSC in the splenocytes of TB and
control mice. Control (n=3) compared to TB (n=3) mice **p,0.01; ***p,0.001 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g006
Figure 7. Loss of homeostasis and function of MDSC in splenocytes from TB mice. (A) Western blot analysis of phospho-AKT-1 (Ser473)
and BCL-2 protein expression in Gr-1
+ enriched MDSC splenocytes from TB and control mice. To control for equal protein loading the blot was re-
probed with an antibody specific for b-actin. (B) TB Gr1
+ MDSC significantly suppress antigen-specific T cell responses (OT-I specific (CD8
+) T cells
primed with OVA-peptide pulsed DC (DC-OVA)) compared to control Gr1
+ MDSC in vitro. Controls for the assay included T cells incubated alone in
complete medium (CM) or DC-OVA. Control (n=3) compared to TB (n=3) mice. **p,0.01; ***p,0.001 (by two-tailed Student’s t test).
doi:10.1371/journal.pone.0027729.g007
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homeostasis in this model.
Ghansah et al reported a loss of homeostasis and function of
MDSC in SHIP deficient mice whereas Collazo et al detailed
similar findings in Treg [16,19]. Huang et al reported that a sub-
population of MDSC causes the induction and expansion of
immunosuppressive Treg that also suppress T cell immune
responses [46]. Treg play a key role in maintenance of self-
tolerance and immune homeostasis [47]. It is possible that release
of IL-10 and other unidentified soluble factors from murine
Panc02 cells may lead to the induction and activation of Treg in
TB mice. We know based on flow cytometry studies that there is a
significant increase in CD4
+CD25
+CD127
2 Treg population in
PB and splenocytes (data not shown) of TB mice as compared to
control mice. We are further characterizing these Treg by
evaluating their expression of the transcription factor Foxp3 and
their ability to suppress antigen-specific T cell responses.
These findings give insight into the regulation of MDSC in a
murine pancreatic cancer microenvironment. Our findings also
highlight that there is a possible role of SHIP-1 in solid tumor
progression and as a tumor suppressor in this pancreatic cancer
model. This may translate to other cancer models in which this
particular phenotype is observed. Tumor-induced MDSC have
been a challenge to many immunotherapeutic strategies including
cancer vaccines. Our study opens a new therapeutic avenue of
potentially targeting SHIP-1 expression, which may directly or
indirectly alleviate immune suppression associated with MDSC.
Therefore, the use of therapeutic agents that modulate SHIP-1
expression will provide more insight into the possible role of SHIP-
1 as a tumor suppressor in solid tumors such as pancreatic cancer.
Materials and Methods
Cell culture
The Panc02 murine pancreatic adenocarcinoma cell line was
established by Corbett et al. by implanting cotton thread
impregnated with 3-methylcholanthrene into the pancreas of
C57BL/6 mice, followed by serial in vivo passage through repeated
transplantation [48]. This cell line was maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS),
(HyClone, Logan, UT, USA), 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin (Gibco BRL, Rockville, MD,
USA) at 37uC in 5%CO2. Cultured cells were tested and found to
be negative for mycoplasma and viral contamination.
Mice
Pathogen-free female C57BL/6 (6–8 weeks old) mice were
purchased from Harlan Laboratories, Inc (Indianapolis, IN). OT-I
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). All mice were maintained in a pathogen-free animal facility
for at least 1 week before each experiment. The Institutional
Animal Care and Use Committee of the University of South
Florida approved all protocols in compliance with the Guide for
the Care and Use of Laboratory Animals. C57BL/6 mice were
injected subcutaneously (s.c.) with 1.5610
5 Panc02 murine cells
(tumor-bearing (TB)) or 100 ml PBS (control) on the right ventral
abdomen. Established tumors were measured every three days
using a digital caliper and spleens were harvested and weighed at
the end of the study.
Cytometric Bead Array Immunoassay
Peripheral blood was collected from control and TB mice and
allowed to clot at room temperature for 2 hours. Serum was
centrifuged at 2,000 rpm for 10 minutes, collected and stored at
220uC until assays were performed. Supernatant was collected
from cultured Panc02 cells. Serum and supernatant concentrations
of IL-6, IL-10, MCP-1, IFN-c, TNF and IL-12p70 were
simultaneously measured using a CBA Mouse Inflammation Kit
(BD Biosciences, San Diego, CA). Briefly, 50 mL of chemokine
capture bead mixture was incubated with 50 mL of each
recombinant standard or sample and 50 mL PE-conjugated
detection antibody for 2 hours at room temperature. The mixture
was then washed to remove unbound PE detection reagent before
data acquisition on a BD LSRII using flow cytometry. Analysis
was performed using FCAP Array software.
Western Blot Analyses
Splenocytes were harvested from control and TB mice and
single-cell suspensions were prepared using a Cell Dissociation
Sieve (Tissue Grinder) (Sigma-Aldrich) and 70 mm cell strainers
(BD Falcon). Red Blood Cells (RBCs) were lysed using RBC Lysis
Buffer (eBioscience). Whole and Gr-1
+ (MDSC) enriched spleno-
cytes from control and TB mice were made into protein lysates
using modified RIPA Buffer (Millipore, MA) containing Na3OV4
and protease inhibitor cocktail (Sigma-Aldrich, MO). Protein
concentrations of these lysates were determined using the BCA
Protein Assay Kit (Thermo Fisher Scientific, IL), according to the
manufacturer’s protocol. 15 mg and 60 mg of whole and Gr-1
+
enriched protein lysates, respectively, were loaded per lane,
resolved using NuPAGEH 4–12% Bis-Tris polyacrylamide Gels
(Invitrogen, CA) and transferred to a nitrocellulose membrane
(Whatman, NJ). The membranes were blocked with 5% nonfat
milk, 1XPBS and 0.1% Tween-20 and then probed with the
following antibodies: anti-SHIP-1 (PIC1) (Santa Cruz, CA) at a
1:200 dilution, anti-Phospho-AKT-1 (Ser473) (Santa Cruz, CA) at
a 1:200 dilution, anti-AKT1/2/3 (Santa Cruz, CA) at a dilution of
1:200, anti-Phospho BAD (Ser112) (Santa Cruz, CA) at a dilution
of 1:200, anti-BAD (Santa Cruz, CA) at a dilution of 1:200, anti-
BCL-2 at a dilution of 1:1000 (Cell Signaling, MA), anti-SHIP-2 at
a dilution of 1:1000 (Cell Signaling, MA), anti-PTEN at a dilution
of 1:1000 (Cell Signaling, MA) Proteins were detected by
secondary antibodies, anti-rabbit IgG, anti-mouse IgG HRP-
linked, (Cell Signaling, MA), at a dilution of 1:1000 or anti-goat
IgG HRP-linked at a dilution of 1:5000 (Santa Cruz, CA).
Secondary antibodies were identified using Super Signal West Pico
and Femto Chemiluminescent Substrate (Thermo Fisher Scientif-
ic, IL), according to the manufacturer’s protocol. All blots were
stripped and re-probed with anti-b-actin (Sigma-Aldrich, MO) at a
dilution of 1:20,000, as an internal control for equal protein
loading. Membranes were exposed to x-ray films (Phenix, NC) and
developed using a Kodak M35-X OMAT Processor. Western blot
bands were quantified using a ChemiDoc XRS Imaging System
and Quantity One 1-D densitometry analysis software (Bio-Rad,
CA).
Quantitative RT-PCR
Single-cell suspensions of whole splenocytes from control and
TB mice were prepared as previously described. Total RNA was
extracted using TRI Reagent (Molecular Research Center),
according to the manufacturer’s protocol. cDNA was synthesized
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) from total RNA (1 mg). mRNA levels for
SHIP-1 were detected by qRT-PCR using SYBR Green
JumpStart Taq Ready Mix (Sigma-Aldrich) and an AB StepOne-
Plus Real-Time PCR System using the following conditions: 95uC
for 10 min followed by 40 cycles of 95uC for 15 sec and 60uC for
1 min. The following primers were used: SHIP-1 forward, 59-
GAG CGG GAT GAA TCC AGT GG-39, reverse, 59-GGA CCT
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triplicate. GAPDH was amplified as the internal control and
reference gene. The relative mRNA frequency was determined by
normalization to the endogenous control GAPDH and calculated
using the Comparative CT method.
In vitro Panc02 Experiments
Single-cell suspensions of control splenocytes were prepared as
previously described. 5610
5 control splenocytes were co-cultured
in vitro with confluent murine Panc02 cells or cultured alone in 6-
well plates for 5 hours. Splenocytes in suspension were separated
from adherent Panc02 cells and analyzed for SHIP-1 mRNA and
protein expression using qRT-PCR and Western Blot analyses, as
previously described.
Flow Cytometry
Single-cell suspensions of whole splenocytes from Control and
TB mice were prepared as previously described and were stained
in PBS/3%FBS with antibodies against MDSC surface markers
CD11b (Mac-1) (FITC) (eBioscience), Ly6G and Ly6C (Gr-1)
(APC) (BD Pharmingen). Flow Cytometry was done using a BD
LSRII Flow Cytometry System (BD Biosciences Immunocytome-
try Systems) and data analyzed with FlowJo software (Tree Star
Inc.)
AutoMACS Gr1
+ Enrichment and Suppression Assay
Whole splenocytes from control and TB mice were processed
into single-cell suspensions, as previously described. Gr-1
+ cells
were purified from whole splenocytes by positive selection using
anti-Gr-1-PE and anti-PE-magnetic microbeads on an Auto-
MACS Pro Separator. Sorted control and TB MDSC were co-
incubated 1:10 with OT-I specific (CD8
+) T cells primed with
bone marrow-derived dendritic cells pulsed with 10 mg/ml
OVASIINFEKL peptide (DC-OVA), for 3 days in vitro. T cell
proliferation was measured by
3H incorporation during the final
12 hours of the culture. Controls for the assay included OT-I
specific T cells incubated alone in complete medium (CM) or with
DC pulsed with OVA peptide (DC-OVA) [49].
Statistical Analysis
All in vitro experiments described in this study are representative
of at least three independent analyses. All in vitro assays and flow
cytometry results were analyzed with two-tailed Student’s t test
using PRISM 5 software (GraphPad, San Diego, CA). Differences
were considered significant at p,0.05.
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